Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

Phase 3

Completed

• Conditions: Bacterial Vaginosis; Mixed Vaginal Infections; Candidal Vulvovaginitis; Trichomonal Vaginitis
• Interventions: Drug: EVEGYN B; Drug: Gynomax® XL Vaginal Ovule; Drug: EVEGYN A

• Registration Number: NCT06056947
• Lead Sponsor: Ege University

Brief Summary

Efficacy and safety of two new formulations compared to Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections was evaluated in this randomized, three-arms, multicentral study.

Detailed Description

This was a national, randomized, 3-arms, phase III study conducted in 16 centers in Türkiye.

It was aimed to evaluate the efficacy and safety of different fixed dose vaginal ovule formulations of fenticonazole + tinidazole + lidocaine (Formulation A and Formulation B) in the treatment of bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis and mixed infections with comparison to Gynomax® XL vaginal ovule.

Study Timeline

• Study Start: 2020-07-20
• Primary Completion: 2021-05-06
• Study Completion: 2021-08-26
• Status Verified: 2023-09
• Study First Submitted: 2023-09-13
• Study First Submitted QC: 2023-09-25
• Last Update Submitted: 2023-09-25
• Study First Posted: 2023-09-28
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 577

Inclusion Criteria

1. Female patients with age of ≥ 18 and ≤ 55 years who have a regular menstrual cycle (at least 10 times a year)
2. Female patients who previously experienced vaginal intercourse
3. Patients requiring treatment for bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis or mixed infections according to the investigator's decision
4. Signed informed consent

Exclusion Criteria

1. Known hypersensitivity to active ingredients (including their derivatives) of the study medications
2. Vaginismus, endometriosis, dyspareunia
3. Detection of urinary tract infection in urinalysis
4. Pancreatitis, hypertriglyceridemia, liver diseases, benign or malign tumors and ongoing organ failure
5. Usage of herbal medicines and drugs that interfere with microsomal enzymes, especially cytochrome P450 (phenytoin, phenobarbital, primidone, carbamazepine, rifampicin, topiramate, felbamate, griseofulvin, HIV protease inhibitors such as ritonavir, nucleoside reverse transcriptase inhibitors such as efavirenz)
6. History of cardiovascular event
7. Uncontrolled diabetes and hypertension
8. Presence or known risk or of venous or arterial thromboembolism
9. Undiagnosed abnormal vaginal bleeding, bleeding disorders, bleeding due to intrauterine device implantation during study period, presence of genital tumors
10. Use of drugs containing ombitasvir / paritaprevir / ritonavir or dasabuvir during or two weeks before initiation of the study
11. Pregnancy and/or breastfeeding
12. Participation in any other trial 30 days before initiation of the study
13. Postmenopausal women
14. Chronic alcoholism
15. Patients with organic neurological disorders
16. Patients with blood dyscrasia or with a history of blood dyscrasia
17. Usage of medications containing acenocoumarol, anisindione, dicoumarol, phenindione, phenprocoumon, warfarin, cholestyramine, cimetidine, cyclosporine, disulfiram, fluorouracil, fosphenitoin, ketoconazole, lithium, rifampin, tacrolimus or propranolol
18. Presence of a sexually transmitted disease such as syphilis, gonorrhea, chlamydia etc. according to the investigator's decision
19. Patients who cannot perform sexual abstinence during the study
20. Patients whose treatment may be affected due to sagging of uterus or any other anatomical disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN B)	EVEGYN B	EVEGYN B is a fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule.
Gynomax® XL Vaginal Ovule	Gynomax® XL Vaginal Ovule	Gynomax® XL is a fixed-dose combination of 300 mg tinidazole + 200 mg tioconazole nitrate + 100 mg lidocaine
fenticonazole + tinidazole + lidocaine vaginal ovule (EVEGYN A)	EVEGYN A	EVEGYN A is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule.

Primary Outcome Measures

Name	Time	Method
Percentage of patients who had complete response to treatment according to clinical findings	13 days (+/- 5 days) after treatment	Efficacy

Secondary Outcome Measures

Name	Time	Method
Frequency and percentage of patients with SAEs/AEs in each arm	13 days (+/- 5 days)	Safety
Percentage of patients who recovered according to microbiological findings	13 days (+/- 5 days) after treatment	Efficacy
Percentage of patients who had partial response to treatment according to clinical findings	13 days (+/- 5 days) after treatment	Efficacy

Trial Locations

Locations (1)

Ege University Family Planning and Infertility Application and Research Center; 🇹🇷 Izmir, Turkey